There is a certain insidious truth to the title of this piece. The war on cancer is a never-ending one, because cancer is multifaceted, and there isn’t any one specific type of cure. Furthermore, internationally modernity encourages behavior that systematically facilitates the development of cancerous ailments. From alcoholism to smoking, from untested genetically modified foodstuffs to aspartame and its cancer/Alzheimer’s linkage, and even negative health developments which stem from technology use, cancer isn’t just a genetic predisposition. Radiation, medication, and a marked lack of exercise also characterize cancerous populations. As a result, biotech companies facilitating demonstrably effective cancer treatments stand to be perpetually stable, stock-wise, and even increase in affluence over time. Following are several biotech organizations with a specialization geared toward treating and preventing cancer.
Medivation and Prostate Cancer (MDVN)
Firstly, Medivation already has a prostate cancer drug out that’s garnered them billions. It’s likely they’ll have a second drug of such caliber out by 2017, and possibly even this year. Medivation has also bought out the rights to other cancer-treating drugs like talazoparib. Medivation purchased talazoparib from BioMarin (BMRN), and paid just shy of half a billion for it ($410 million). Talazoparib is classified as a PARP inhibitor. Used for a certain kind of breast cancer patients that have already undergone numerous therapies and are beset with a certain gene mutation which makes PARP inhibitor use amenable. In it’s third phase, should the conclusions be successful in 2016’s middle, it’s likely the drug will be approved soon afterward.
Other similar inhibitors of the PARP variety have been approved already, making it likely Medivation’s acquisition will prove lucrative. One in ten patients of breast cancer have the specific mutation required to make talazoparib effective. Statistics show that about twelve percent of all women will suffer from breast cancer in their lives. Assuming a US population of 323,000,000, that means approximately 3,876,000 will need medication like talazoparib on a regular basis.
Celldex Therapeutics and Brain Cancer (CLDX)
Celldex‘ new drug Rintega was delayed by clinical trials in August, but should it be successful during the third phase of testing, it will very likely become one of the highest sellers in brain cancer medications through the 2016 year. As of the second phase, the drug has been able to stall the growth of malignancies in the brain among patients of glioblastoma. Utilizing a drug called Avastin and a certain control agent, Rintega became the third musketeer in a cancer-fighting triad that actually cut the risk of death down forty-three percent among those on whom it was tested. By the fourth quarter, those final trial results should be in. It could happen sooner, and that’s one of the reasons why Celldex is worth keeping an eye on in the coming months.
Lung Cancer and Clovis Oncology (CLVS)
There’s a drug called rociletinib that’s geared at those suffering from lung cancer. Clovis has data which indicates six out of ten patients with a certain mutation do well with this drug. Positive results like that could very well facilitate an approval from the Federal Drug Administration. The kind of cancer rociletinib treats afflicts most of the 400,000 Americans currently living with lung cancer.
Should rociletinib be as impacting as it is expected to be, their stock will see a definite jump. But you can’t put all your eggs in one basket with pharmaceuticals, and that’s why Clovis is also on the hook for a PARP inhibitor of their own; rucaparib. This one is aimed at ovarian cancer, and apparently is five percent more effective on patients who would benefit from its use than rociletinib.